Roivant CEO sells 289,774 common shares

Roivant Sciences CEO Matthew Gline reported an open-market sale of 289,774 common shares at a weighted average price of $29.16 per share.

Rhea-AI Filing Summary

Roivant Sciences CEO Matthew Gline reported an open-market sale of 289,774 common shares at a weighted average price of $29.16 per share. According to the filing, the trades occurred across multiple transactions between $28.98 and $29.36. After these sales, he directly owns 16,736,116 common shares.

Insider Trade Summary

Net Seller: 289,774 shares

Net Sell 1 txn

Insider Gline Matthew

Role CEO

Sold 289,774 shs ($8.45M)

Type	Security	Shares	Price	Value
Sale	Common Shares	289,774	$29.16	$8.45M

Holdings After Transaction: Common Shares — 16,736,116 shares (Direct)

Footnotes (1)

1. F1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.98 to $29.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

Key Figures

Shares sold: 289,774 shares Weighted average sale price: $29.16 per share Post-transaction holdings: 16,736,116 shares +2 more

5 metrics

Shares sold 289,774 shares Common Shares sold in open-market transaction

Weighted average sale price $29.16 per share Average price for reported sales

Post-transaction holdings 16,736,116 shares Common Shares directly owned after sale

Sale price range low $28.98 per share Lowest price in reported sale range

Sale price range high $29.36 per share Highest price in reported sale range

Key Terms

open-market sale, weighted average price, Form 4

3 terms

open-market sale financial

"transaction_action is described as an open-market sale of Common Shares"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average price financial

"The price reported in column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Form 4 regulatory

"INSIDER FILING DATA (Form 4) describes the reported insider transaction"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Roivant Sciences (ROIV) disclose for Matthew Gline?

Roivant Sciences CEO Matthew Gline disclosed an open-market sale of 289,774 common shares. The transaction was reported on Form 4 and reflects a routine insider sale while he continues to hold a large direct stake in the company following the trades.

How many Roivant Sciences (ROIV) shares did Matthew Gline sell and at what average price?

Matthew Gline sold 289,774 Roivant common shares at a weighted average price of $29.16. The filing notes the shares were sold in multiple transactions within a narrow intraday range, rather than a single block trade at one fixed price.

What price range did Matthew Gline’s Roivant (ROIV) share sales occur within?

The reported sales occurred at prices ranging from $28.98 to $29.36 per share. The Form 4 explains that the $29.16 figure is a weighted average, and that detailed information on the number of shares sold at each price is available upon request.

How many Roivant Sciences (ROIV) shares does Matthew Gline hold after this Form 4 sale?

After the reported sale, Matthew Gline directly holds 16,736,116 Roivant common shares. This post-transaction ownership figure comes from the Form 4 and shows he retains a substantial position in the company despite the recent share disposition.

What does a weighted average sale price mean in Matthew Gline’s Roivant (ROIV) Form 4?

A weighted average price means the 289,774 shares were sold in many trades at slightly different prices. The $29.16 figure reflects the combined effect of all those trades, and the filing offers to provide exact breakdowns on request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/20/2026 - 06:27 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gline Matthew

(Last) (First) (Middle)

C/O ROIVANT SCIENCES LTD.

7TH FLOOR, 50 BROADWAY

(Street)

LONDON SW1H 0DB

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	04/16/2026		S		289,774	D	$29.16(1)	16,736,116	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.98 to $29.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

Remarks:

	By: /s/ Jo Chen, as Attorney-in-Fact for Matthew Gline	04/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)